Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin + Metformin in PCOS
NCT04973891Phase 2Completed
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of canagliflozin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Body mass index at 3 months. Started Apr 2021; status: completed.
02
Drugs
canagliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT04973891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973891.